GS

Gilead Sciences is a leading global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for life-threatening diseases. The company is a dominant force in the virology market, having transformed the treatment of HIV and Hepatitis C with curative and long-acting therapies. Gilead has strategically expanded its portfolio into oncology and inflammation through major acquisitions, including Kite Pharma for cell therapy and Immunomedics for antibody-drug conjugates. Its robust pipeline features numerous investigational compounds, many identified by the 'GS' prefix, targeting high-unmet needs in viral hepatitis, solid tumors, and autoimmune disorders. Headquartered in Foster City, California, Gilead operates in more than 35 countries and is committed to advancing global health equity.